Babylon Health Files for IPO: AI-Powered Telemedicine Leader Backed by Samsung and Tencent

The Past Is a Rehearsal for the Future.

As early as the April 1924 issue of Radio News magazine, the cover featured a vision of “The Radio Doctor”—a physician who would obtain patients’ diagnostic data via proprietary equipment and provide treatment recommendations remotely. In that nascent era of technology, this cover story was more akin to a glimpse into the future.

“Radio News,” cover of the April 1924 issue

It was not until the 1950s and 1960s that the remote transmission of patient medical data was truly realized: in 1959, radiologists at Jean-Talon Hospital in Montreal achieved remote transmission of X-ray images using television camera technology; in 1969, a Veterans Administration hospital in Oklahoma accomplished remote transmission of electrocardiographic monitoring data.

It was not until the late 1980s, with the utilization of satellites and Integrated Services Digital Network (ISDN) in Europe, the United States, and other countries, that telemedicine achieved substantial breakthroughs, witnessing rapid advancements in remote consultations and remote medical image transmission.

European and American countries have been continuously exploring telemedicine and formulating policies to remove obstacles to its development. In the United States, for example, the ten-year health IT plan during the Bush administration and the Affordable Care Act under Obama have both been favorable to the growth of telemedicine.

And ultimately, a dream from nearly a century ago,With the comprehensive coverage of the Internet and the widespread adoption of smartphones, truly reaching communities and individuals, has become a reality.

Today, with the public listings of TelaDoc (a telemedicine service provider) and Amwell (a telemedicine solutions provider), MDLive, a first-tier telemedicine company, also plans to file for an IPO early next year. The future of telemedicine may already be foreshadowed by the companies currently adopting advanced technologies to develop their telemedicine services.

Among them, Babylon Health (hereinafter referred to as “Babylon”), an AI-enabled telemedicine company that has adopted AI technology and secured hundreds of millions of dollars in financing, stands out as a highly representative enterprise. What are the distinctive features of the AI technology employed by Babylon? And what insights has it offered for the development of telemedicine?

Whether it is TelaDoc, Amwell, or MDLive, they are all typical American companies. However, Babylon is different,It is a European company from London, UK, established in 2013.Its European attributes mean that the market and regulatory environments it faces differ from those of U.S. companies. In October 2019, an article titled “Europe’s doctor apps, compared” provided a broad overview of the top 14 digital health startups in Europe (each with funding exceeding €1 million). This may offer insights into Babylon’s standing.

August 2019,Babylon secured $550 million in financing, bringing its cash holdings to a level exceeding the combined total of all other companies on the list.Kry and MinDoktor ranked second and third, respectively. Although the number of downloads does not equate to the actual number of users, it can still serve as a reference. In terms of download volume, Babylon ranked second with 1.217 million downloads, while Kry took the top spot with 1.226 million downloads. Doktor.se, which ranked third, had only 564,000 downloads, showing a significant gap. In reality,As of October 2019, Babylon had facilitated more than 2 million online consultations.Kry ranks second, with 1.2 million consultations. MiniDoktor, in third place, recorded only 600,000 consultations. This competition resembles a contest among wealthy and powerful enterprises.

The fragmented landscape of multiple European countries has created numerous obstacles for the development of startups.France did not pass legislation permitting the online provision of medical diagnoses and treatments until late 2018. It was not until August 2019 that Germany legalized the dispensing of medications without a prior physician consultation. In contrast, UK regulators have maintained an open stance, encouraging innovation and other initiatives, which has fostered robust growth among digital healthcare service providers. Although Sweden boasts a favorable environment, frequent government adjustments to financing interest rates have often disappointed startups.

Considering the above factors,More digital health startups are emerging in countries with favorable regulatory environments and are increasingly targeting other nations with similarly supportive regulatory frameworks.For instance, in 2018, Kry launched its new brand “livi,” targeting new markets outside the Nordic region.Babylon set its sights on the global market, conducting business worldwide and providing digital healthcare services to partners in Rwanda, Canada, Southeast Asia, and Saudi Arabia. With increased capital investment, it has strategically targeted the United States and Asia.. This is also one of the factors that distinguish it from other European telemedicine companies.

Babylon, like other companies in the telemedicine sector, provides 24/7 services that include personalized health assessments, treatment recommendations, and online consultations. Through the Babylon GP at Hand app, users can consult with general practitioners anytime via smartphone or video call.

Since its inception, Babylon has secured three rounds of financing.In January 2016, it secured $25 million in Series A financing.Investors in this funding round include Demis Hassabis and Mustafa Suleyman, founders of DeepMind (acquired by Google in 2014). Rumors have long circulated that Babylon is integrating DeepMind’s AI to deliver healthcare services through an AI-powered chatbot, enabling patients to gain preliminary insights into their condition prior to text-, audio-, or video-based consultations.

In April 2017, Babylon secured £47 million (approximately $60 million) in financing.For Ali Parsa, founder and CEO of Babylon—the entrepreneur who previously established Circle, Europe’s largest clinician collaboration network—this funding round aims to accelerate the clinical certification of its existing AI chatbot by the UK’s MHRA and the US FDA, thereby creating aMore Complex Medical Diagnostic Robots.

Founder and CEO Ali Parsa

In August 2019, it secured $550 million in financing.This was also the largest financing round in Europe’s digital health sector at that time. The primary purpose of the funding was to expand Babylon’s business,Extend it to the United States and Asia, and further develop needleAI Diagnostic Platform for Severe Chronic Diseases.

From its developmental trajectory, it is clear that Babylon has transitioned from an AI-powered medical service chatbot to an AI platform for chronic disease diagnosis. This shift reflects Babylon’s recognition of the large population of chronic disease patients in the current market. Subsequently, Babylon made its first investment in the United States.

In May 2020, Babylon led a $30 million Series B investment in Higi, an intelligent healthcare service provider.Higi itself operates 10,000 FDA-cleared self-service smart health kiosks, serving an audience of over 62 million people by providing personalized recommendations for local care resources and services.Through collaboration, Babylon can provide more end-to-end solutions to meet the frontline needs of payers, providers, and retailers in delivering care services.

Babylon believes that what sets it apart from other healthcare providers is its adoption of AI. Babylon stated that its services were inspired by the citizens of ancient Babylon 2,500 years ago, who commonly shared treatments for common diseases in the city center. Babylon considers ancient Babylon to be one of the earliest existing examples of healthcare democratization, and attributes the fact that ancient Babylonians had nearly the longest life expectancy in the ancient world to this practice.

Specifically, Babylon believes that the biggest problem with traditional healthcare lies in the pre- and post-consultation phases. They have chosen to leverage AI to enhance the efficiency of physician consultations.By integrating existing medical data to create a comprehensive medical encyclopedia and understanding relationships among diseases, symptoms, and medication matching, Babylon’s AI can help users determine whether they need to consult a doctor, identify the underlying causes of their conditions, and even assess and predict their future health status.

Babylon’s AI is primarily built around four pillars: a knowledge base, comprehensive health records, probabilistic graphical models, and simulations. At its core is a digital medical encyclopedia (i.e., the knowledge base), which encompasses the characteristics and interrelationships of various diseases, symptoms, and treatments. Babylon also collects users’ medical histories and data generated through interactions, gradually developing personalized solutions. Leveraging artificial intelligence, it simulates the ongoing effects of individuals’ dietary, exercise, sleep, and stress patterns, helping users understand the impact of their behaviors and enabling Babylon to develop optimized care plans.

Furthermore, Babylon is continuously reading and learning from patient health records, including consultation records from clinicians using the Babylon app in different countries. Babylon is constantly addressing the challenges posed by varying terminology and descriptions for the same medical conditions.Through continuous learning, Babylon is improving the accuracy of its AI diagnostics and delivering increasingly personalized services through enhanced user interactions.

Babylon provides users withAI symptom inquiry, general practice (gradually extending to specialty) remote consultations (with in-person options available in select cities), prescription issuance, health tracking and testing services, and provides family account services. Users can consult the Babylon AI chatbot at any time, with medical inquiries during this process being completely free of charge. Its primary diagnoses include food poisoning, infectious mononucleosis, stomach pain, and more. A fee is required when users consult doctors via online medical consultations.

For employer clients,Babylon charges employers a fee of £3.75 per employee per month.Users can perform symptom self-checks at any time and consult with virtual general practitioners, psychiatrists, nurses, and pharmacists via video. They can also obtain prescriptions directly from nearby pharmacies or have them delivered to their doorstep, while simultaneously monitoring and tracking their health status. Its corporate clients include BNP PARIBAS, Heathrow, HSBC, CISCO, and BuzzFeed, among others.

In addition, it also offers flexible payment plans for general practitioners.Users can choose to pay a one-time fee of £49 or an annual fee of £149 for consultations. The costs for one-time consultations with clinicians or specialists vary slightly between subscribers and non-subscribers. For consultations with clinicians, subscribers pay £39, while non-subscribers pay £59. For consultations with specialists, subscribers pay £49, whereas non-subscribers pay £79.

Babylon has also entered into a collaboration with the NIH. As early as January 2017, the two parties launched a six-month partnership to replace the NHS 111 telephone hotline with an AI-powered chatbot. The telephone hotline was frequently busy or failed to provide appropriate clinical advice. Babylon was responsible for triaging “urgent but non-life-threatening conditions,” helping patients check their symptoms and offering the most suitable recommendations. However, this service was somewhat limited, as patients could not obtain prescriptions or be referred for online consultations.

In addition to offering users relatively affordable solutions, Babylon also provides general practitioners with more attractive compensation packages to recruit those withGMC-Registered PhysicianProvide services to it.

In addition to its initial collaboration with the NIH to alleviate pressure on offline outpatient services, Babylon has also been expanding its commercial footprint during its development.

In 2018, it entered into partnerships with Tencent and Samsung. In particular, its collaboration with Tencent, which boasts a massive user base, facilitated its entry into the Chinese market via WeChat (despite the crowded landscape of internet healthcare companies in China at the time). This also marked a significant attempt by Babylon to leverage AI algorithms to integrate with the products of internet giants for disease assessment.

Beyond continuous experimentation, Babylon is also accelerating the iterative management of its AI products.

In September of the same year, Babylon announced a $100 million investment to expand its team of engineers and scientists, doubling its headcount from 500 to 1,000. Through this move,Babylon aims to enhance its capabilities in managing chronic conditions such as diabetes and depression.Babylon aims to develop technologies capable of assessing patients’ overall health status and monitoring chronic diseases.

January 2020,It has launched a triage chatbot service tailored to the U.S. market.To adapt to the U.S. context, it has hired American staff and adjusted its AI natural language processing system. Meanwhile, the product has also undergone certain modifications based on the unique services and regulatory policies of the U.S. healthcare industry.

Meanwhile, Babylon has entered into a partnership with the Royal Wolverhampton NHS Trust (RWT) in the UK.Both parties jointly developed an application that, while providing remote diagnostic services, enables real-time monitoring of patients with chronic diseases through wearable devices and other monitoring programs. The app allows patients to remotely contact physicians when needed and, through its integrated monitoring features, facilitates improved patient self-management.

In March 2020, Babylon launched a symptom-tracking app in response to the COVID-19 pandemic.The results of product exploration and iteration emerged this April, with Babylon claiming that its AI can accurately triage 85% of patients.

Despite its rapid development, the debate surrounding Babylon has never ceased.

The controversy stems primarily from two aspects: first, the concern that it is competing for the UK’s already scarce pool of general practitioners; and second, questions regarding whether its AI technology can replace general practitioners and whether it has led to an increase in misdiagnoses.

In October 2016, the Royal College of General Practitioners (RCGP) publicly endorsed Babylon, introducing it to the public as a sponsor. At the event, Babylon stated that general practitioners, whether working part-time or full-time, could earn higher incomes through its app. The Patients AssociationChief Executive Officer Katherine Murphy believes that the RCGP’s endorsement of the enterprise is disgraceful, and that redirecting NHS general practitioners—who are already in short supply—to serve private companies violates medical ethics.

This has compelled Mobasher Butt, Babylon’s Medical Director, to express support for doctors conducting online consultations outside of regular working hours. “General practitioners can balance family and career, and they greatly value the flexibility this offers.” In fact, the UK healthcare landscape features numerous private hospitals and for-profit institutions attracting GPs away from the public sector, with Babylon being just one among them.The most fundamental issue is actually the shortage of general practitioners. While Babylon improves the efficiency of general practitioners, it inevitably infringes upon the interests of some parties by recruiting them.

When Babylon announced in 2018 that it had passed the MRCGP exam—the final assessment for trainee general practitioners set by the RCGP—and achieved a higher score than human doctors (with an average human pass rate of 72% compared to Babylon’s 81%), the claim immediately drew skepticism from the RCGP.

Professor Martin Marshall, Vice Chair of the RCGP, stated that while the technological potential to support physicians in delivering optimal patient care is highly promising, computers are ultimately just computers,General practitioners are well-trained medical professionals; the two are not comparable. The former may support the latter but will never replace it.

In fact, the greater concern may not be whether AI will replace human doctors, but whether Babylon’s artificial intelligence has led to misdiagnoses. Initially, British society, and particularly the NIH, was supportive of Babylon, largely because the UK was projected to spend nearly $200 billion on its National Health Service by 2020, equivalent to 7% of its GDP. There was an urgent need for an institution to help alleviate this pressure.

Babylon’s use of artificial intelligence to help patients determine whether they need medical access aligns perfectly with the NIH’s approach. In fact, when the NIH 111 hotline relied on human advisors, approximately 20% of callers were referred for in-person consultations; after adopting Babylon, this figure rose to as high as 30%.However, since Babylon did not ultimately track this data, it is impossible to determine whether the number of people seeking medical care actually increased or decreased.

Meanwhile, Babylon has also been accused by its former employees and external parties of lacking genuine clinical assessment and follow-up. No data were retained on how many patients ultimately sought hospital care or what their diagnoses were. Complaints against Babylon have even surfaced on Twitter, prompting an investigation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA); however, Babylon stated, ““Even experienced doctors sometimes make incorrect diagnoses.”

In reality, telemedicine startups must contend with a host of other challenges beyond facing various skepticism. For instance, Babylon faced allegations in June of this year for compromising user privacy. The issue stemmed from a vulnerability during an app update that allowed users to access video consultation data belonging to other patients. For companies, timely and continuous monitoring and updates are the only means to patch such vulnerabilities.

In terms of funding, even the leading telemedicine companies are all startups. Large technology companies have not invested heavily in this field. Of course, we have recently seen some changes, such as Google’s partnership with Amwell.

From a regulatory perspective, challenges persist regarding overseas insurance reimbursement and subsidies, as well as domestic health insurance payment mechanisms. In the United States, federal Medicare agencies took the lead in relaxing all restrictive provisions on telemedicine and virtual health consultations, while easing Health Insurance Portability and Accountability Act (HIPAA) restrictions to allow cross-state telemedicine services. The Dutch government previously announced €400 million in funding to support the advancement of digital healthcare. China has also institutionalized policies that promoted the development of internet-based healthcare during the pandemic.

However, challenges in the development of telemedicine persist. The future still seems to be unfolding.